Advertisement
Screener

Spruce Biosciences, Inc. (SPRB) Long-Term Debt, Maturity, Year Five

2.8 / 5 stars · 68/120 Roast Me

Spruce Biosciences, Inc. Long-Term Debt, Maturity, Year Five

Spruce Biosciences, Inc. (SPRB) had Long-Term Debt, Maturity, Year Five of $135.00 thousand as of 2022-09-30, per its 10-Q filed 2022-11-10.

Discontinued › Notes › Commitment and Contingencies

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2022-11-10

  • 2022-09-30: Long-Term Debt, Maturity, Year Five $135.00K.
  • 2021-12-31: Long-Term Debt, Maturity, Year Five $135.00K.
Period endLong-Term Debt, Maturity, Year Five
2022-09-30$135.00K
10-Q · filed 2022-11-10
2021-12-31$135.00K
10-K · filed 2022-03-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Korro Bio, Inc. (KRRO)United States$0.141B-1.81
Atrium Therapeutics, Inc. (RNA)United States$0.140B
Corbus Pharmaceuticals Holdings, Inc. (CRBP)United States$0.144B-1.72
Curanex Pharmaceuticals Inc (CURX)United States$0.138B
Annexon, Inc. (ANNX)United States$0.147B-4.22
TuHURA Biosciences, Inc./NV (HURA)United States$0.134B-4.88
Unicycive Therapeutics, Inc. (UNCY)United States$0.134B-3.70
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31
MEDICINOVA INC (MNOV)United States$0.130B-6.04
IMMUNIC, INC. (IMUX)United States$0.127B-1.88